Trump administration signals international pricing index, importation rules are advancing

The Trump administration Wednesday published clues about pending proposed rules that would create a foreign reference pricing benchmark for Medicare Part B drug prices and allow importation of prescription drugs.

The White House Office of Management and Budget’s (OMB) biannual regulatory agenda includes a November target for releasing a notice of proposed rulemaking for an International Pricing Index (IPI) model for Medicare Part B drugs. There is no legal requirement for OMB to meet the release date. ...